NSG 555 Quiz 2

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/299

encourage image

There's no tags or description

Looks like no tags are added yet.

300 Terms

1
New cards
Diabetes diagnosis: A1c threshold
6.5% or higher
2
New cards
Diabetes diagnosis: fasting plasma glucose threshold
126 mg/dL or higher, after no calories for at least 8 hours
3
New cards
Diabetes diagnosis: 2-hour oral glucose tolerance test threshold
200 mg/dL or higher, using a 75 gram glucose load
4
New cards
Diabetes diagnosis: random glucose threshold
200 mg/dL or higher, PLUS classic symptoms (excessive thirst, excessive urination, unexplained weight loss) or a hyperglycemic crisis
5
New cards
Diabetes diagnosis: the confirmation rule
Two abnormal results are required - either two different tests from the same blood draw, or the same test repeated on a separate day. Exception: a random glucose of 200 or more with classic symptoms or a crisis stands alone.
6
New cards
Prediabetes: A1c range
5.7 to 6.4%
7
New cards
Prediabetes: fasting glucose range
100 to 125 mg/dL
8
New cards
Prediabetes: 2-hour oral glucose tolerance test range
140 to 199 mg/dL
9
New cards
When is A1c falsely LOW
When red cells die or are replaced early: hemolytic anemia, recent transfusion, recent bleeding, pregnancy, erythropoietin or iron therapy, sickle cell disease
10
New cards
When is A1c falsely HIGH
When red cells live longer: iron deficiency anemia, vitamin B12 deficiency, after splenectomy
11
New cards
When is A1c unpredictable
Advanced or end-stage kidney disease; hemoglobinopathies such as sickle cell trait and beta thalassemia
12
New cards
Alternatives to A1c when it is unreliable
Fructosamine, glycated albumin, or continuous glucose monitoring
13
New cards
A1c goal for most non-pregnant adults
Under 7%
14
New cards
When to aim for an A1c under 6.5%
Short duration of diabetes, long life expectancy, no cardiovascular disease, achievable without hypoglycemia
15
New cards
When to loosen the A1c goal to under 8% or higher
Limited life expectancy, advanced complications, history of severe hypoglycemia, hypoglycemia unawareness, extensive other illness. Tight control prevents microvascular complications over many years; a patient who will not live to collect that benefit is only exposed to hypoglycemia risk.
16
New cards
Time in range (continuous glucose monitoring)
Percentage of time glucose is between 70 and 180 mg/dL. Goal is above 70%, roughly 17 hours per day.
17
New cards
What does A1c NOT tell you that CGM does
A1c gives a 3-month average and cannot tell you WHEN glucose is high or low. Two patients with the same A1c can have completely different variability and hypoglycemia exposure.
18
New cards
Repeatedly low overnight on CGM suggests
Too much basal insulin
19
New cards
Type 1 diabetes: mechanism
Autoimmune destruction of pancreatic beta cells producing ABSOLUTE insulin deficiency
20
New cards
Type 2 diabetes: mechanism
Insulin resistance plus progressive loss of adequate beta-cell insulin secretion - a RELATIVE deficiency
21
New cards
Why does type 1 diabetes cause DKA
Insulin normally suppresses fat breakdown and ketone production. With absolute deficiency, free fatty acids are released from fat tissue, delivered to the liver, and converted into ketone bodies.
22
New cards
Antibodies in type 1 diabetes
GAD-65, islet cell, and insulin autoantibodies - absent in type 2
23
New cards
C-peptide in type 1 vs type 2
Low or undetectable in type 1; normal or high in type 2
24
New cards
LADA
Latent autoimmune diabetes in adults - an adult who looks like type 2 but is thin, fails oral agents quickly, and has autoantibodies. Age alone never rules out type 1.
25
New cards
Atypical features that should prompt antibody and C-peptide testing
Rapid progression, weight loss, ketosis, or unexpectedly early insulin dependence
26
New cards
The safety rule when diabetes type is uncertain
Never delay needed insulin in a patient who appears insulin deficient or metabolically unstable. Treat the instability first; classify later.
27
New cards
Screening for type 2 diabetes
All adults starting at age 35, or earlier at any age with BMI 25 or more (23 or more in Asian Americans) plus a risk factor. Repeat every 3 years if normal, annually if prediabetic.
28
New cards
Classic symptoms of hyperglycemia
Polyuria, polydipsia, polyphagia, blurred vision, fatigue, recurrent infections, unintentional weight loss
29
New cards
Why does hyperglycemia cause polyuria
Once filtered glucose exceeds the kidney's reabsorptive capacity, glucose stays in the urine and pulls water with it - osmotic diuresis - driving thirst, dehydration, and electrolyte loss
30
New cards
Red flags that move a hyperglycemic patient out of the routine outpatient pathway
Altered mental status, hypotension, Kussmaul respirations, severe dehydration, persistent vomiting
31
New cards
Acanthosis nigricans
Velvety dark thickening of skin at the neck, axillae, and skin folds - a visible marker of insulin resistance
32
New cards
Why do you need BOTH eGFR and urine albumin-to-creatinine ratio in diabetes
eGFR estimates filtration; the albumin-to-creatinine ratio identifies kidney damage and cardiovascular risk EVEN WHEN eGFR is still preserved. They answer different questions.
33
New cards
Blood pressure drug of choice in diabetes with albuminuria
ACE inhibitor or ARB - they protect the kidney beyond their blood pressure effect. Never both together.
34
New cards
Differential diagnosis of hyperglycemia
Type 1 (including adult-onset autoimmune), type 2, gestational, monogenic forms (MODY), pancreatic or exocrine disease, drug- or chemical-induced, stress hyperglycemia from acute illness, and endocrine disorders (Cushing's, acromegaly, thyroid disease)
35
New cards
Most common drug cause of clinically significant hyperglycemia
Glucocorticoids. Some antipsychotics also worsen insulin resistance and weight.
36
New cards
Does stress hyperglycemia from acute illness rule out diabetes
No - it does not automatically exclude underlying diabetes
37
New cards
Diabetic neuropathy: classic presentation
Distal symmetric polyneuropathy - burning and numbness in BOTH feet, often worse at night, starting distally and moving up (stocking-and-glove)
38
New cards
Diabetic neuropathy: how to examine
10-gram monofilament for protective sensation PLUS at least one other modality - vibration (128 Hz tuning fork), pinprick, temperature, or ankle reflexes
39
New cards
Should you order EMG and nerve conduction studies for typical diabetic neuropathy
No - do not reflexively order them for a typical case. The evaluation is clinical.
40
New cards
When to refer or test further in diabetic neuropathy
Atypical features: asymmetry, prominent motor weakness, rapid progression, upper-extremity onset, or an unclear diagnosis
41
New cards
Treatable causes to rule out in diabetic neuropathy
Vitamin B12 deficiency (especially on long-term metformin), thyroid disease (TSH), plus CBC and comprehensive metabolic panel; serum protein electrophoresis in selected cases
42
New cards
Diabetes complication surveillance: retinal exam
At diagnosis in type 2 (within 5 years in type 1), then annually
43
New cards
Diabetes complication surveillance: kidney
Urine albumin-to-creatinine ratio and eGFR at least annually
44
New cards
Diabetes complication surveillance: feet
Look at every visit; comprehensive exam with monofilament annually
45
New cards
Microvascular vs macrovascular complications
Microvascular (retinopathy, nephropathy, neuropathy) are driven by how high the glucose runs and for how long. Macrovascular (coronary disease, stroke, peripheral artery disease) are driven by the whole risk-factor cluster and respond more to blood pressure control, statins, and smoking cessation than to A1c alone.
46
New cards
Diabetes drug selection: patient has established cardiovascular disease
GLP-1 agonist OR SGLT2 inhibitor with proven cardiovascular benefit, regardless of A1c and regardless of whether metformin is already being used
47
New cards
Diabetes drug selection: patient has heart failure
SGLT2 inhibitor
48
New cards
Diabetes drug selection: patient has chronic kidney disease
SGLT2 inhibitor; selected GLP-1 agonists also provide kidney and cardiovascular benefit
49
New cards
Diabetes drug selection: weight reduction is the priority
GLP-1 agonist or dual GIP/GLP-1 therapy (tirzepatide)
50
New cards
Which diabetes drug classes cause hypoglycemia on their own
Only sulfonylureas, meglitinides, and insulin. Everything else needs a partner drug to cause a low.
51
New cards
Which diabetes drug classes cause weight GAIN
Sulfonylureas, meglitinides, thiazolidinediones, and insulin. The incretins and SGLT2 inhibitors cause weight loss.
52
New cards
Metformin: mechanism
Reduces liver glucose production and improves insulin sensitivity. It does not force the pancreas to make insulin, which is why it does not cause lows.
53
New cards
Metformin: kidney cutoffs
eGFR 45 or above - normal use. eGFR 30 to 44 - do not START new; reassess dose and risk if already taking it. eGFR BELOW 30 - contraindicated, stop.
54
New cards
Metformin and contrast imaging
Hold before contrast if eGFR is under 60, and for 48 hours afterward
55
New cards
Metformin and vitamin B12
Long-term use causes B12 deficiency. Check the level when clinically indicated, particularly with anemia or new numbness.
56
New cards
Metformin: A1c reduction and weight effect
1.0 to 2.0% A1c reduction; weight neutral or slight loss
57
New cards
SGLT2 inhibitor: mechanism
Blocks glucose reabsorption in the kidney so glucose is excreted in the urine
58
New cards
SGLT2 inhibitor: benefits
A1c reduction 0.4 to 1.1%; weight loss around 6 pounds sustained at 2 years; reduced major cardiovascular events including death and heart failure hospitalization; improved kidney outcomes; more effective than DPP-4 inhibitors
59
New cards
SGLT2 inhibitor: approved uses beyond diabetes
Heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease - all with or without diabetes
60
New cards
SGLT2 inhibitor limitations caused by sugar in the urine
Genital yeast infection (about 9.5%, poor choice in incontinent patients); urinary tract infection (10 to 15% of women); risk of urosepsis and pyelonephritis; rarely necrotizing fasciitis of the perineum; phimosis in uncircumcised men
61
New cards
SGLT2 inhibitor limitation caused by the shift to burning fat
Ketoacidosis, including EUGLYCEMIC ketoacidosis - the glucose can look near-normal while the patient is in full DKA
62
New cards
SGLT2 inhibitor: amputation-risk caution
Relative contraindication in patients at high amputation risk - severe neuropathy, prior foot ulcers, peripheral artery disease, Charcot joint. Fracture risk mainly with canagliflozin.
63
New cards
SGLT2 inhibitor sick-day rules
Hold during acute illness, prolonged fasting, before surgery (3 to 4 days), or with very low carbohydrate intake - because of euglycemic DKA risk
64
New cards
GLP-1 agonist: mechanism
Amplifies the incretin effect - increases the body's own insulin release when glucose is high, suppresses glucagon, slows gastric emptying, and reduces appetite. Can lower A1c by up to about 1.9%.
65
New cards
GLP-1 agonist: absolute contraindications
Personal or family history of medullary thyroid carcinoma, or MEN-2 syndrome (boxed warning)
66
New cards
GLP-1 agonist: other cautions
Avoid in type 1 diabetes, severe gastroparesis, and pregnancy. Prior pancreatitis is a relative contraindication. Go slow with existing retinopathy, because rapid A1c lowering can transiently worsen it.
67
New cards
GLP-1 agonist vs insulin in type 2 diabetes
A GLP-1 agonist is preferred over insulin when injectable therapy is needed
68
New cards
Tirzepatide
A dual GIP and GLP-1 receptor agonist with the greatest glycemic and weight effects of any class
69
New cards
DPP-4 inhibitors: mechanism and profile
Block the enzyme that breaks down the body's own incretins. Weight neutral, low hypoglycemia risk, modest glucose lowering (0.5 to 0.8%).
70
New cards
DPP-4 inhibitors and kidney function
Most require renal dose adjustment. LINAGLIPTIN is the notable exception - it is cleared mainly through bile rather than the kidney.
71
New cards
Which DPP-4 inhibitors raise heart failure hospitalization
Saxagliptin and alogliptin
72
New cards
Sulfonylureas: mechanism and main risk
Force the pancreas to release insulin regardless of the glucose level - which is why hypoglycemia is the major concern. Also cause weight gain.
73
New cards
Which sulfonylurea is particularly problematic in older adults and kidney disease
Glyburide - because of prolonged hypoglycemia risk
74
New cards
Meglitinides
Repaglinide and nateglinide - shorter-acting, dosed around meals. Still carry hypoglycemia and weight gain risk. Skip the dose if the meal is skipped.
75
New cards
Thiazolidinediones: mechanism and main concerns
Improve insulin sensitivity through PPAR-gamma activation. Concerns: weight gain, fluid retention, fracture risk, and WORSENING HEART FAILURE - contraindicated in heart failure.
76
New cards
Alpha-glucosidase inhibitors
Acarbose - delays carbohydrate absorption and blunts after-meal glucose. Gastrointestinal effects limit use.
77
New cards
Pramlintide
An amylin analog used as an adjunct to mealtime insulin in selected patients. Slows gastric emptying, suppresses after-meal glucagon, and increases satiety.
78
New cards
Colesevelam and bromocriptine
Less commonly used glucose-lowering agents. Colesevelam is a bile acid sequestrant; bromocriptine is a dopamine agonist. Know they exist and the general mechanism; they are not first choices.
79
New cards
When is insulin needed in type 2 diabetes
When hyperglycemia is severe, when symptoms or catabolism suggest insulin deficiency, during acute illness or pregnancy, or when non-insulin therapy is insufficient
80
New cards
The two major insulin-related concerns
Hypoglycemia and weight gain
81
New cards
Basal insulin: what it does
Suppresses liver glucose production between meals and overnight. Roughly 50% of the total daily dose.
82
New cards
Prandial (bolus) insulin: what it does
Covers carbohydrate-related glucose rises at meals. The other 50%, split across meals.
83
New cards
Starting basal insulin in type 2 diabetes
10 units at bedtime, or 0.1 to 0.2 units per kilogram per day. Titrate by 2 units every 3 days based on the fasting morning glucose. Keep metformin going.
84
New cards
Rapid-acting insulin: examples and profile
Aspart (NovoLog), lispro (Humalog), glulisine (Apidra). Onset about 15 minutes, peak 0.5 to 2 hours, duration under 5 hours.
85
New cards
Rapid-acting insulin: timing
Inject 5 to 15 minutes BEFORE the meal - food needs to be in front of the patient within about 15 minutes
86
New cards
Faster rapid-acting insulin
Faster aspart (Fiasp) and inhaled human insulin (Afrezza). Onset 12 to 15 minutes, peak 0.5 to 2 hours, duration 1.5 to 7 hours.
87
New cards
Short-acting (regular) insulin: profile and timing
Humulin R, Novolin R. Onset about 30 minutes, peak 2 to 5 hours, duration about 8 hours. Give 30 MINUTES before the meal.
88
New cards
Intermediate-acting insulin
NPH (Humulin N, Novolin N). Onset about 90 minutes, peak 4 to 8 hours, duration up to 24 hours. Its pronounced peak increases hypoglycemia variability.
89
New cards
Long-acting insulin
Glargine (Lantus, Basaglar) and detemir (Levemir). Minimal or no peak. Glargine lasts about 24 hours; DETEMIR'S DURATION IS DOSE-DEPENDENT and often needs twice-daily dosing.
90
New cards
Ultra-long-acting insulin
Degludec (Tresiba) - no peak, duration up to 42 hours, flexible timing
91
New cards
Is Xultophy an insulin
No - it is a COMBINATION of insulin degludec plus liraglutide (a GLP-1 agonist), not a pure insulin
92
New cards
Which insulin is standard in DKA protocols
Intravenous regular (short-acting) insulin - not a rapid analog
93
New cards
The type 1 diabetes sick-day safety rule
Basal insulin cannot simply be stopped because the patient is not eating. A person with type 1 makes no insulin at all, so stopping basal lets ketone production start within hours and can cause DKA. Doses may need adjustment, but basal continues.
94
New cards
Low glucose in the middle of the night or before breakfast suggests
The evening basal or NPH dose is too high
95
New cards
Low glucose before lunch suggests
The morning rapid-acting dose was too high
96
New cards
Hypoglycemia levels
Level 1: below 70 mg/dL (alert value). Level 2: below 54 mg/dL (clinically significant). Level 3: any level with altered mental status requiring another person's help (severe).
97
New cards
Hypoglycemia: the two waves of symptoms
First adrenergic - tremor, palpitations, sweating, anxiety, hunger, paresthesia. Then neuroglycopenic as the brain runs short of fuel - confusion, behavior change, visual disturbance, seizure, loss of consciousness.
98
New cards
Hypoglycemia: the rule of 15
15 grams of fast-acting carbohydrate, recheck in 15 minutes, repeat if still under 70. Then give a meal or a snack with protein. If the patient cannot swallow safely, use glucagon or IV dextrose.
99
New cards
Hypoglycemia unawareness
The adrenergic warning symptoms stop happening after repeated lows, so the patient goes straight to confusion. Treatment is to deliberately loosen targets for a few weeks to let the warning system reset.
100
New cards
What to do after any significant hypoglycemic episode
Determine why it happened and modify the regimen. Recurrent hypoglycemia is not an acceptable trade-off for a lower A1c.